Skip to content
Loracarbef
Lorabid (loracarbef) is a small molecule pharmaceutical. Loracarbef was first approved as Lorabid on 1991-12-31. It is used to treat bacterial infections, female genital diseases, infectious bone diseases, infectious skin diseases, and joint diseases amongst others in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
musculoskeletal diseasesD009140
respiratory tract diseasesD012140
otorhinolaryngologic diseasesD010038
urogenital diseasesD000091642
skin and connective tissue diseasesD017437
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Loracarbef
Tradename
Company
Number
Date
Products
LORABIDKing PharmaceuticalsN-050667 DISCN1991-12-31
2 products
LORABIDKing PharmaceuticalsN-050668 DISCN1991-12-31
2 products
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
bacterial infections—D001424A49
female genital diseasesEFO_0009549D005831N85
infectious bone diseases—D001850—
infectious skin diseases—D012874—
joint diseasesHP_0003040D007592M12.9
otitis mediaEFO_0004992D010033H66.9
sinusitisEFO_0007486D012852J32
urinary retentionHP_0000016D016055R33
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
J: Antiinfectives for systemic use
— J01: Antibacterials for systemic use
— J01D: Other beta-lactam antibacterials in atc
— J01DC: Second-generation cephalosporins
— J01DC08: Loracarbef
HCPCS
No data
Clinical
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameLORACARBEF
INNloracarbef
Description
Loracarbef is a synthetic "carba" analogue of cefaclor, with carbon replacing sulfur at position 1. Used to treat a wide range of infections caused by both gram-positive and gram-negative bacteria. It has a role as an antibacterial drug and an antimicrobial agent. It is a conjugate acid of a loracarbef anion. It is a tautomer of a loracarbef zwitterion.
Classification
Small molecule
Drug classantibiotics (carbacephem derivatives)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
N[C@@H](C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(Cl)CC[C@H]12)c1ccccc1.O
Identifiers
PDB—
CAS-ID76470-66-1
RxCUI28981
ChEMBL IDCHEMBL1200610
ChEBI ID—
PubChem CID5284585
DrugBankDB00447
UNII IDW72I5ZT78Z (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 298 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
39 adverse events reported
View more details